Research programme: pneumococcal vaccine conjugate - Sinovac Biotech

Drug Profile

Research programme: pneumococcal vaccine conjugate - Sinovac Biotech

Alternative Names: Pneumococcal 13-valent vaccine - Sinovac Biotech

Latest Information Update: 31 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sinovac Biotech
  • Class Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Pneumococcal infections

Most Recent Events

  • 31 Dec 2017 Pneumococcal vaccine conjugate is still in preclinical trials for Pneumococcal infections in China
  • 01 Jan 2015 China FDA approves Clinical Trial Application for 13-valent Pneumococcal conjugate vaccine candidate
  • 31 Mar 2011 Sinovac Biotech files a Clinical Trial application with the China FDA for its 13-valent Pneumococcal conjugate vaccine candidate
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top